JP2018518522A - 癌を治療するための組成物及び方法 - Google Patents

癌を治療するための組成物及び方法 Download PDF

Info

Publication number
JP2018518522A
JP2018518522A JP2017567214A JP2017567214A JP2018518522A JP 2018518522 A JP2018518522 A JP 2018518522A JP 2017567214 A JP2017567214 A JP 2017567214A JP 2017567214 A JP2017567214 A JP 2017567214A JP 2018518522 A JP2018518522 A JP 2018518522A
Authority
JP
Japan
Prior art keywords
cancer
pp2a
inhibitor
kinase inhibitor
protein kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017567214A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018518522A5 (enExample
Inventor
ナルラ，ゴーサム
オールメイヤー，マイケル
マクアイド，ダニエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Icahn School of Medicine at Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School of Medicine at Mount Sinai filed Critical Icahn School of Medicine at Mount Sinai
Publication of JP2018518522A publication Critical patent/JP2018518522A/ja
Publication of JP2018518522A5 publication Critical patent/JP2018518522A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2017567214A 2015-06-23 2016-06-23 癌を治療するための組成物及び方法 Pending JP2018518522A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562183517P 2015-06-23 2015-06-23
US62/183,517 2015-06-23
PCT/US2016/039022 WO2016210134A1 (en) 2015-06-23 2016-06-23 Compositions and methods for treating cancer

Publications (2)

Publication Number Publication Date
JP2018518522A true JP2018518522A (ja) 2018-07-12
JP2018518522A5 JP2018518522A5 (enExample) 2019-07-25

Family

ID=57586472

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017567214A Pending JP2018518522A (ja) 2015-06-23 2016-06-23 癌を治療するための組成物及び方法

Country Status (8)

Country Link
US (1) US10744141B2 (enExample)
EP (1) EP3313819A1 (enExample)
JP (1) JP2018518522A (enExample)
CN (1) CN108779073A (enExample)
AU (1) AU2016281646A1 (enExample)
CA (1) CA2990835A1 (enExample)
IL (1) IL256523A (enExample)
WO (1) WO2016210134A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023519931A (ja) * 2020-04-01 2023-05-15 エンジン バイオサイエンシズ プライベート リミテッド 癌を治療するための方法及び組成物

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2999177A1 (en) 2015-09-24 2017-03-30 The Regents Of The University Of California Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
WO2021188949A1 (en) * 2020-03-20 2021-09-23 Atux Iskay Llc 3-diarylmethylenes and uses thereof
WO2022094615A1 (en) * 2020-10-29 2022-05-05 The Regents Of The University Of California Compounds and methods for increased antisense activity
CN114617969B (zh) * 2020-12-14 2023-08-25 上海市肿瘤研究所 乐伐替尼和Aurora-A激酶抑制剂在制备抑制癌症的药物中的应用
JP2024508687A (ja) * 2021-02-08 2024-02-28 ラプタ セラピューティクス オーワイ プロテインホスファターゼ２ａ（ｐｐ２ａ）の置換環状調節物質およびこれを用いた方法
CN112816453B (zh) * 2021-02-09 2022-07-08 黑龙江大学 蛋白在预测药物性能上的应用
CN113616795B (zh) * 2021-08-31 2023-06-20 上海交通大学医学院附属瑞金医院 Pp2a激动剂防治由正常衰老或pp2a活性或表达降低所导致的精神障碍
CN114984221A (zh) * 2022-05-25 2022-09-02 浙江大学 Pp2a及其激活剂在急性缺血性脑卒中制药、标记的应用
CN116421726A (zh) * 2023-04-14 2023-07-14 中国海洋大学 一种基于分子预测的靶向plk1纳米药物的开发方法
WO2025230951A1 (en) * 2024-04-29 2025-11-06 Icahn School Of Medicine At Mount Sinai Method of treating adenoid cystic carcinoma

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030045515A1 (en) * 2001-05-24 2003-03-06 Lise Binderup Combination medicament for treatment of neoplastic diseases
EP1996193A2 (en) * 2006-03-13 2008-12-03 OSI Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
US20090020197A1 (en) * 2007-07-16 2009-01-22 Key Safety Systems, Inc. Gas generating compositions and airbag inflators
WO2009114703A2 (en) * 2008-03-12 2009-09-17 Fox Chase Cancer Center Combination therapy for the treatment of cancer
WO2009117769A1 (en) * 2008-03-25 2009-10-01 Newcastle Innovation Limited Inhibition of c-kit cancers
WO2010120711A1 (en) * 2009-04-13 2010-10-21 The Ohio State University Research Foundation Protein phosphatase 2a-activating agents
US9134297B2 (en) * 2011-01-11 2015-09-15 Icahn School Of Medicine At Mount Sinai Method and compositions for treating cancer and related methods
HK1198384A1 (en) * 2011-08-16 2015-04-17 Mt. Sinai School Of Medicine Tricyclic compounds as anticancer agents
JP2015500885A (ja) * 2011-12-22 2015-01-08 スレッショルド ファーマシューティカルズ，インコーポレイテッド 癌を治療するためのｃｈｋ１阻害剤と組み合わせた低酸素活性化プロドラッグの投与
US20140357573A1 (en) * 2013-03-15 2014-12-04 Life Technologies Corporation Prognostic assay for squamous cell lung carcinoma
WO2015138496A1 (en) 2014-03-11 2015-09-17 Icahn School Of Medicine At Mount Sinai Constrained tricyclic sulfonamides
US9937186B2 (en) 2014-03-11 2018-04-10 Icahn School Of Medicine At Mount Sinai Sulfonamides derived from tricyclyl-2-aminocycloalkanols as anticancer agents

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CLIN CANCER RES, vol. 20, no. 8, JPN6020020499, 2014, pages 2092 - 103, ISSN: 0004284881 *
LANCET ONCOL, vol. 14, no. 6, JPN6020020501, 2013, pages 229 - 38, ISSN: 0004284882 *
MOL ONCOL, vol. 9, no. 4, JPN6020020498, April 2015 (2015-04-01), pages 889 - 905, ISSN: 0004284880 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023519931A (ja) * 2020-04-01 2023-05-15 エンジン バイオサイエンシズ プライベート リミテッド 癌を治療するための方法及び組成物

Also Published As

Publication number Publication date
US10744141B2 (en) 2020-08-18
CN108779073A (zh) 2018-11-09
IL256523A (en) 2018-02-28
US20180185382A1 (en) 2018-07-05
AU2016281646A1 (en) 2018-02-01
EP3313819A1 (en) 2018-05-02
WO2016210134A1 (en) 2016-12-29
CA2990835A1 (en) 2016-12-29

Similar Documents

Publication Publication Date Title
US10744141B2 (en) Compositions and methods for treating cancer
JP6963146B1 (ja) 癌を治療するためのｋｒａｓ阻害剤の投与
JP2022058398A (ja) Ｂｒａｆ－ｖ６００関連疾患の治療に使用するためのｐｌｘ－８３９４またはｐｌｘ－７９０４
US11096947B2 (en) Combination products with tyrosine kinase inhibitors and their use
JP6838085B2 (ja) Ｔｏｒキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法
US20090226422A1 (en) Chemical Inhibitors of Inhibitors of Differentiation
UA119537C2 (uk) ЗАСТОСУВАННЯ ЗАМІЩЕНИХ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНІВ ДЛЯ ЛІКУВАННЯ ЛІМФОМ
KR102221005B1 (ko) 전립선암 치료를 위한 디하이드로피라지노-피라진 화합물 및 안드로겐 수용체 길항제를 포함하는 조합 요법
EA030465B1 (ru) Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
CN102648200A (zh) 用于治疗cns病症的8-乙基-6-(芳基)吡啶并[2，3-d]嘧啶-7(8h)-酮
JP2019505541A (ja) Ｒｓｋ阻害剤として有用なカルボキサミド誘導体
CN107207510B (zh) 联合疗法
WO2020047487A1 (en) Methods for treating cancer with rorgamma inhibitors and statins
CN115867551A (zh) 单一疗法和组合疗法
EP1885187B1 (en) Methods for treating drug resistant cancer
JP2018510134A (ja) 組合せがん治療法
JP2021100972A (ja) がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ
US20190117663A1 (en) Compositions and methods for treating cancer
HK40064964A (en) Combination products with tyrosine kinase inhibitors and their use
CN117355304A (zh) Alk-5抑制剂及其用途
HK1110477B (en) Methods for treating drug resistant cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190619

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200616

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210126